Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Option on Rosetta Public Offering; Total Gross Proceeds Rise to $31.6M

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the underwriter for its recent public offering has exercised an overallotment option to purchase 825,000 additional shares of the company's common stock, bringing the total gross proceeds from the offering to $31.6 million.

Aegis Capital was the sole book-running manager on the offering. Rosetta completed the public offering of 5.5 million shares at $5 per share earlier this month.

Proceeds will go toward general corporate purposes including repayment or refinancing of debt, capital investments, and R&D and product development efforts, the Israel-based developer of microRNA-based molecular diagnostics previously said.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.